FSD Pharma to Present at Arcview Investor Forum

biospace | April 17, 2019

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), announced today that Dr. Raza Bokhari, Co-Chairman and Chief Executive Officer of FSD Pharma will participate in the Arcview Investor Forum being held April 23-25, 2019, in Vancouver. The event will feature leading public and private companies and thought leaders who are shaping the future of the industry. Dr. Bokhari will be the keynote speaker and participate in panels discussing issues affecting the future of the industry, including regulatory environment, financing and consumer trends. Dr. Sara May, the recently appointed president of FV Pharma, will participate in a panel about investing in plant genetics. FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company has 25,000 square feet available for production at its Ontario facility with an additional 220,000 square feet currently in development.

Spotlight

The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day. Today's video highlights include Acorda Therapeutics, tozadenant, AstraZeneca, Fasenra, FDA, Cardinal Health and Shanghai Pharmaceuticals.

Spotlight

The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day. Today's video highlights include Acorda Therapeutics, tozadenant, AstraZeneca, Fasenra, FDA, Cardinal Health and Shanghai Pharmaceuticals.

Related News

AmerisourceBergen & Global Pharmaceutical Manufacturers Discuss “Moving Health Forward” at Second Annual ThinkLive Trade Virtual Conference

AmerisourceBergen | October 22, 2021

Today, AmerisourceBergen concluded its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand, specialty, generic and consumer-product manufacturers. Over the course of the event, AmerisourceBergen leaders discussed the ever-evolving challenges and considerations that these manufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply chain sophistication, maximize patient access, and move health forward. AmerisourceBergen also introduced its new President of Manufacturer Services and Commercial Solutions, Willis Chandler, during the conference – a new role for the organization.“The last two years have proven how dynamic, fast-paced and essential the pharmaceutical industry and supply chain are to advancing global health—from launching new therapies, to maintaining consistent access to daily prescriptions, to providing frontline workers with the products and resources they need to stay safe amid a pandemic,” said Willis Chandler, who recently stepped into the new role as President of Manufacturer Services and Commercial Solutions from leading AmerisourceBergen’s health systems and specialty services organization. “ThinkLive Trade is an opportune time for us connect with manufacturers and dig deeper into their needs, challenges and opportunities in the year ahead. I plan to carry our key learnings from the conference forward, and I cannot wait to bring more novel solutions to the market in collaboration with our manufacturer partners.” This year’s conference programming included remarks from AmerisourceBergen Chairman, President & CEO Steve Collis, dynamic panel discussions, presentations, awards, virtual networking sessions and more. Content and meetings were facilitated through AmerisourceBergen’s online experience platform, AmerisourceBergenLive. On the first day of the summit, attendees heard directly from AmerisourceBergen executives and customers on the state of the industry, strategies to improve global health equity, and sustainable and responsible approaches to healthcare advancement. Day two of ThinkLive Trade featured discussions on technology and infrastructure enhancements to drive innovation, supply chain continuity​, and AmerisourceBergen’s strategy and focus for the year ahead. The final day of the summit focused on the intersection of healthcare and politics, featuring a fireside chat with, Mark McClellan, MD, PhD, founding Director of the Duke-Margolis Center for Health Policy at Duke University, as well as timely discussions on global generics, specialty pharmaceutical products, biosimilars, and more. “The resilience of the pharmaceutical supply chain in the face of a global pandemic and evolving market dynamics continues to reinforce the value of strategic relationships, Our partners are developing novel therapeutics, creating pharmaceuticals to manage chronic conditions in patients worldwide, producing essential generics to ensure cost-effective medicines are available in today’s marketing, developing consumer products that are essential to fighting this pandemic and beyond, and so much more. We are thankful for their partnership and to all who attended ThinkLive Trade. This week’s conference encouraged meaningful dialogue that will help us advance healthcare efficiency and supply chain reliability in the year ahead.” Janine Burkett, SVP & President, Strategic Global Sourcing at AmerisourceBergen. AmerisourceBergen will also host ThinkLive Commercialization early next year. The event will bring together emerging biotech and biopharma leaders to discuss the latest in launch strategies across different therapeutic categories. About AmerisourceBergen AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies, and providers, we create unparalleled access, efficiency, and reliability for human and animal health. Our 41,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue

Read More

PRACTICE MANAGEMENT

AvKARE bottles mix Viagra generics with antidepressant, triggering recall

AvKARE | December 15, 2020

A conventional drugmaker with a Rolodex loaded with government customers is pulling an energizer and an erectile brokenness medications after the two were bundled together in similar containers. Pulaski, Tennessee-based AvKARE reviewed one parcel of sildenafil 100-mg tablets and one parcel of trazodone 100-mg tablets after the items were stirred up by an outsider bundling provider, the organization said before the end of last week. The jugs had just been delivered to drug stores. AvKARE markets its own private-name conventional medications to a record of government customers, including the branches of Defense, Veterans Affairs and the Health and Human Services. The organization additionally supplies the Indian Health Services, in addition to nongovernment clients around the world. The customer level review influences parts sent to merchants and wholesalers and afterward delivered out from one side of the country to the other, the organization said. The sildenafil part has a March 2022 termination date, while the trazodone parcel lapses in June 2022. AvKARE said it so far hasn't got any result reports from the reviewed parcels. Sildenafil—a nonexclusive rendition of Viagra—can blend inadequately with nitrate-containing drugs for diabetes, hypertension or coronary illness, conceivably bringing pulse down to perilous levels. The upper trazodone hydrochloride, in the interim, can cause sluggishness, dazedness, stoppage and obscured vision, AvKARE cautioned. Those results represent a more serious danger of falls and impeded driving in more seasoned clients who may have bought the organization's erectile brokenness copycat.

Read More

PHARMA TECH

Aidoc and Subtle Medical Partner to Bring End-to-End AI Solutions to Medical Imaging

Aidoc | September 15, 2021

Aidoc, leading provider of AI for medical imaging, announced today a partnership with Subtle Medical, developer of leading AI-based image enhancement bringing best-of-breed AI to both image acquisition and post-acquisition clinical workflows. Aidoc has developed the industry's most robust AI platform, delivering a unified and seamless cross-specialty AI experience for physicians in over 500 medical centers, including the largest clinical deployment of AI in healthcare at Radiology Partners. "Mainstream healthcare adoption of AI requires both a comprehensive package of premier AI solutions and an ability to deliver their results in a reliable and seamless manner across physician workflow, Through this partnership, we will provide health systems and imaging centers with Subtle Medical's optimal solution, now seamlessly delivered through a unified AI architecture. Our platform's ability to deliver interoperable AI solutions is a game changer for AI adoption." - Tom Valent, VP of Business Development at Aidoc. A pioneer in healthcare AI, Aidoc's FDA-cleared solutions analyze medical images for critical conditions and trigger actionable alerts directly in the imaging workflow supporting medical specialists in reducing turnaround time and improving quality of care. Subtle Medical's AI-powered software solutions, SubtlePET™ and SubtleMR™ are image enhancement tools that increase the efficiency of image capture by improving the quality of accelerated scans. This enables optimized scan times and can potentially increase the number of patients scanned per day. Subtle's solutions are compatible with all scanner brands, models and field strengths so institutions can see the benefit across their entire scanner fleet. "This agreement will provide our customers with a multimodality solution that includes acquisition workflow efficiencies and image quality improvements together with Aidoc's post-acquisition clinical workflow solutions, We believe that the integration of Subtle's AI-based software tools with the Aidoc platform will dramatically change the medical imaging equation." - Josh Gurewitz, Chief Commercial Officer at Subtle Medical. About Subtle Medical Subtle Medical, Inc. is a leading healthcare technology company making medical imaging faster, safer, and smarter. For more information, visit subtlemedical.com. About Aidoc Aidoc is the leading provider of artificial intelligence solutions that support and enhance the impact of physician diagnostic power - helping them expedite patient treatment and improve quality of care.

Read More